Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avian influenza (H9 subtype) inactivated vaccine (NJ01 strain)
- Development stage
- Unknown
- Lead developer
- Youbang Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The avian influenza (H9 subtype) inactivated vaccine (NJ01 strain) is a veterinary biologic developed by Youbang Pharmaceutical for the immunization of poultry and waterfowl against the H9 subtype of the avian influenza virus. The vaccine utilizes the NJ01 strain, which has been inactivated to ensure safety while retaining its ability to stimulate a protective immune response. Upon administration, the vaccine induces the production of specific neutralizing antibodies against the viral hemagglutinin, thereby providing protection against infection and reducing viral shedding. This vaccine is particularly targeted at preventing the economic impact of low-pathogenic avian influenza (LPAI) H9 infections in agricultural settings and is currently approved for veterinary use in China.
- Other names
- 禽流感(H9亚型)灭活疫苗(NJ01株)Avian influenza H9 subtype inactivated vaccine (NJ01 strain)Avian influenza (H9 subtype) inactivated vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on avian influenza (H9 subtype) inactivated vaccine (NJ01 strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avian influenza (H9 subtype) inactivated vaccine (NJ01 strain).